Team 22

Biomedical Engineering Arterial Technologies

Team Members:

Adeline Beeler

Mikayla McNally

Grace Morgan

Team Mentors:

Dr. Jose Maria Reynaldo Apollo Arquiza - Arizona State University

Dr. Kuei-Chun (Mark) Wang - Arizona State University

Joseph Chung - Creighton University

Nick Tan - Creighton University

YouTube Link:
View the video link below before joining the zoom meeting

Zoom Link:
https://asu.zoom.us/j/89263920121

Abstract

In patients experiencing heart failure with preserved ejection fraction (HFpEF), the left ventricle is unable to relax and fill with blood appropriately, causing the heart to rely on the left atrium to fill the left ventricle with blood and pump blood through the heart to other tissues of the body. Over time, the left atrium’s contractility may become compromised, preventing the left ventricle from filling with blood and causing cardiogenic shock for patients, a serious condition that could be fatal. Patients need an implantable device that could bypass the left ventricle and deliver blood from the left atrium to the aorta and the rest of the body. Left ventricular bypasses are typically performed for thoracic aortic aneurysm surgical repair which involves the invasive procedure of implanting and connecting an external pump to the heart for patients at risk of myocardial infarction. A left ventricular bypass pump is used to emulate the function of the left ventricle, connecting the left atrium to the aorta and delivering sufficient blood supply. Current cardiac pumps to bypass the left ventricle are bulky and require highly pressurized transportation of the blood to an external site far removed from the heart. There is a need for a left ventricular bypass that contains the capabilities of advanced devices with a significantly decreased size that fits as a shunt between the left atrium and the aorta. Our proposed device aims to relieve strain from the left atrium and assist in pumping blood to the body through a small, long-term, implantable device. The global cardiovascular market is projected to reach $50.87B USD at a 6.9% CAGR, and the Biomedical Engineering Atrial Technologies’ cardiac pump shunt described above is expected to be competitive within the cardiovascular market.